
|Articles|April 28, 2011
StudyManager Unveils Reveal Version 3.2
Advertisement
StudyManager
announced the release of Reveal 3.2, with enhanced features that provide greater ease of use and performance for research sites, academic medical centers, and hospitals.Reveal 3.2 provides a host of enhanced features focused on greater ease of use and performance including:
- Expanded fields and filters available in Reveal’s reporting tool, allowing clients to include and combine additional patient, scheduling, and financial information on custom views and then export them to Microsoft Excel
- A new, workflow-driven accrual activity “wizard,” making it easier for clients to track their revenue and receivables, create invoices, trigger holdbacks, and apply payments
- Increased performance of numerous key screens, including the Study “Visits & Procedures” screen, allowing clients to more quickly build their study schedule of events in a grid-style format that matches Sponsor documents
- A number of new workflow enhancements requested by clients, such as a new study search/select field that allows users to more quickly identify and select a study for patient enrollment
Reveal features focus on helping sites centralize study information, and:
- Improve clinical trial recruitment and enrollment results
- Negotiate more favorable contracts
- Ensure payment for all study activity–including items that have been historically difficult for sites to track such as screen-fails, holdbacks, and one-time fees
- Support clinical trial compliance efforts including federal patient privacy regulations, clinical compliance with sponsors’ protocols, and billing compliance to eliminate potential for double-billing of multiple payers
- Develop best practices and automate daily tasks to save time, reduce stress, and cut down on mistakes
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Operational Pragmatism in ePRO-heavy trials
2
Why Regulator-Sponsor Alignment Is Critical to Modernizing Trial Execution
3
Could Selective Safety Data Collection Become the Industry's New Default?
4
AI-Enabled Sites and the Future of Trial Planning: Q&A with Liz Beatty, Inato
5




